References in Publication

1. Pharmacopeia US USP <800> Hazardous Drugs - Handling in Healthcare Settings
2. Distefano M, Scambia G, Ferlini C et al. Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int J Cancer. 1997;72(5):844-50.
3. Ehrlichova M, Vaclavikova R, Ojima I et al. Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 2005 Jul;372(1):95-105.
4. Ojima I, Slater JC, Kuduk SD et al. Syntheses and structure-activity relationships of toxoids derived from 14 beta-hydroxy-10-deacetylbaccatin III. J Med Chem. 1997;40(3):267-78.
5. Sampath D, Discafani CM, Loganzo F et al. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol Cancer Ther. 2003;2(9):873-84.
6. Baker SD, Li J, ten Tije AJ et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther. 2005;77(1):43-53.
7. Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995;13(1):180-90.
8. Tije AJ, Verweij J, Carducci MA et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol. 2005;23(6):1070-7.
9. Zamboni WC, Egorin MJ, Van Echo DA et al. Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. J Clin Oncol. 2000;18(18):3288-94.
10. McDevitt JJ, Lees PS, McDiarmid MA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med. 1993;35(1):57-60.
11. NIOSH. Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. NIOSH. 2004(No. 2004-165).
12. Polovich M. Safe handling of hazardous drugs. Online J Issues Nurs. 2004;9(3):6.